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Abstract
Minimal residual disease (MRD) assessment in light of the effectiveness of new multiple myeloma 
(MM) treatment modalities and related to it increasing ratios of achieved complete remissions 
(CR), becomes an important tool in recognition of the depth of the response. Multiparametric flow 
cytometry (MFC) is currently the most popular method for monitoring of MRD presence in bone 
marrow of MM patients; however, molecular techniques may also be used for MRD assessment. 
The choice of protocol utilized for MFC-MRD measurement can significantly affect the obtained 
results, nevertheless standardized and highly sensitive approach of next generation flow (NGF) 
is already available. The depth of response based on MRD assessment was shown to be an inde-
pendent predictor of progression-free survival (PFS) and overall survival (OS). Furthermore, the 
MRD-negative status surpasses the prognostic value of CR achievement for PFS and OS. Thus, 
MRD status detected by highly sensitive and reproducible MFC is potentially a clinically applicable 
biomarker for evaluation of different treatment strategies efficacy potentially influencing treatment 
decisions, and acting as prognostic factor in MM patients.
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Streszczenie
W świetle wysokiej skuteczności nowych metod leczenia szpiczaka plazmocytowego oraz zwiększają-
cego się odsetka osiąganych całkowitych remisji (CR) ocena minimalnej choroby resztkowej (MRD) 
jest obecnie istotną metodą określającą głębokość odpowiedzi. Wieloparametryczna cytometria prze-
pływowa (MFC) jest obecnie najczęściej wykorzystywaną metodą monitorowania MRD w szpiku 
kostnym pacjentów ze szpiczakiem plazmocytowym, jednak w tym celu można również stosować 
metody molekularne. Rodzaj protokołu stosowanego przy badaniu MRD metodą MFC może istotnie 
wpływać na uzyskiwane wyniki, jednak obecnie jest już dostępny wystandaryzowany i wysoce czuły 
protokół cytometrii następnej generacji (NGF). Wykazano, że głębokość odpowiedzi oceniona na 
podstawie pomiaru MRD koreluje z przeżyciem wolnym od progresji (PFS) oraz przeżyciem całko-
witym (OS) chorych na szpiczaka plazmocytowego. Ponadto ujemny wynik badania w kierunku 
MRD jest lepszym czynnikiem prognostycznym w odniesieniu do PFS oraz OS niż osiągnięcie CR. 
Z tych względów wynik oceny MRD, uzyskany wysoce czułą oraz powtarzalną metodą MFC, jest 
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potencjalnie użytecznym klinicznie biomarkerem do oceny skuteczności różnych strategii leczni-
czych i może być podstawą do podejmowania decyzji terapeutycznej oraz użytecznym czynnikiem 
prognostycznym w szpiczaku plazmocytowym.
Słowa kluczowe: szpiczak plazmocytowy, minimalna choroba resztkowa, cytometria 
przepływowa
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Needs for MRD detection
The indicator of treatment effectivity is the 
number of residual clonal cells. Assessment of MRD 
is becoming standard diagnostic care for potentially 
curable neoplasms such as acute lymphoblastic 
leukaemia. In MM, the majority of patients will ine-
vitably relapse despite achievement of progressively 
higher complete response (CR) rates, but new treat-
ment approaches might further increase remission 
rates and potentially cure rates [2]. Interestingly, few 
of patients that reach suboptimal response (near CR 
and/or very good partial response) are relapse free at 
10 years [9]. Paiva et al. [10] already in 2008 demon-
strated the clinical importance of MRD evaluation by 
MFC and illustrated the need for further refinement 
of MM response criteria. Analysis of contribution of 
the serum free light chain ratio (sFLCr) or bone mar-
row (BM) clonality to the prognosis of MM revealed, 
that the sFLCr does not identify patients in CR at 
distinct risk; by contrast, flow cytometry revealed 
patients with a significantly inferior outcome. So the 
achieving of CR does not mean to achieve cure and 
new definition of CR is needed even as stringent 
CR (sCR) is not sufficiently informative in term of 
supposed PFS and/or OS [6]. However, the definition 
of clinical response criteria and clinical end points 
largely remained the same over the past 15 years. 
It was proved that MRD detection is sensitive and 
fast approach to acquire an independent predictor 
of PFS and OS [11, 12]. Even more, as was recently 
demonstrated, MRD-negative status surpasses the 
prognostic value of CR achievement for PFS and 
OS across the disease spectrum, regardless of the 
type of treatment or patient risk group. Thus MRD 
negativity should be considered as one of the most 
relevant end points for transplant-eligible and elderly 
fit patients with MM [13].
Flow cytometric assessment of MRD
Although flow cytometry is not a diagnostic 
tool in MM analyses (where morphology is widely 
available and still plays an irreplaceable role; on 
Introduction
Multiple myeloma (MM) is a hematologic ma-
lignancy characteristic by presence of clonal bone 
marrow plasma cells (PCs). Development of new 
therapies led to the significantly prolonged overall 
survival (OS) in newly diagnosed patients [1]. Ef-
fective treatment comes along with the need for 
more sensitive approaches to compare the efficacy 
of different treatment strategies, and implementa-
tion of individualized therapy monitoring strategies 
to prevent both under- and overtreatment [2]. 
There are still developed new therapeutics, but 
the transition to mainstream availability is much 
slower as randomized phase III clinical trials take 
years to show a benefit when using progression 
free survival (PFS) and OS as study endpoints 
[3]. Extensive data indicate that minimal residual 
disease (MRD) information can potentially be used 
as biomarker to evaluate the efficacy of different 
treatment strategies, help on treatment decisions, 
and act as surrogate for overall survival [2–4]. Con-
firmation of the elimination of myeloma residual 
cell clones resistant to the therapy should be the 
way to cure MM.
There are available techniques on cellular 
(MFC, multiparametric flow cytometry; NGF, 
next generation flow) and/or molecular (qPCR, 
quantitative polymerase chain reaction; NGS, next 
generation sequencing) level including imaging 
methods which allowed to find that persistent MRD 
means worse survival in MM (Table 1) [2, 5–7]. 
MFC seems to be the most effective of existing 
approaches. Development of protocols for MFC-
-MRD followed technical progress of cytometry it-
self, availability of new antigens and fluorochromes 
together with standardization requirements [2, 8]. 
A novel validated NGF assay for high-sensitive, fast 
and standardized quantification of MRD in MM that 
overcomes previous limitations of conventional 
MFC-MRD approaches and improves prediction 
of patient outcome, is ready-to-use and well-suited 
for implementation in clinical trials to establish the 
diagnostic role of MRD in MM [7].
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the other hand, the underestimation of PC number 
by flow cytometry is known), it provides important 
information about the presence and number of 
especially clonal PC. MFC is generally applicable 
to majority of myeloma patients with a sensitivity 
ranging from 10−4 to 10−6. The progress in MFC 
technology and wide availability of used antibodies 
allows MFC to be an integral part of laboratory 
investigations and the management of plasma-cell 
disorders (PCD) and can play an important part in 
the diagnosis, prognostic stratification, and moni-
toring of response to therapy via minimal residual 
disease detection, the understanding of the bio-
logy of disease progression, the study of the role 
of the tumour microenvironment in PCD and the 
identification of potential therapeutic targets on 
the malignant PC (Table 2) [2, 16–18]. Valid and/ 
/or even better standardized MRD detection will 
ensure superior uniform assessment of response 
and clinical prognostication.
MFC in MRD definition
The use of MFC in the detection of MRD in 
BM was demonstrated by several studies from 
2002. The sensitivity of the flow cytometry assay 
was highlighted by the presence of detectable PC 
in nearly a third of the patients with negative im-
munofixation (IFx–) results and patients who were 
MRD-positive (MRD+) had a worse outcome [19, 
20]. Flow cytometry was mentioned for the first 
time in stringent CR (sCR) definition, where absen-
ce of BM clonal cells by immunohistochemistry or 
Table 1. Characteristics of available techniques to monitor minimal residual disease (MRD) in multiple myeloma (source [2])
Tabela 1. Charakterystyka dostępnych technik monitorowania minimalnej choroby resztkowej (MRD) w szpiczaku plazmocy-
towym (źródło [2])
Applicability [%] ~100 60–70 ~90 ~100
Reproducibility High High Not reported Moderated
Availability High Intermediate Limited Intermediate
Diagnostic sample Not mandatory Mandatory Mandatory Not mandatory
Fresh sample Needed (< 36 h) Not needed Not needed NA
Time 2–3 h ≥ 5 days ≥ 7days 2 h
Cost per sample [EUR] ~300 ~450 ~600 ~1800
Sensitivity 10–5–10–6 10–5–10–6 10–6 High
Global cell characterisation Yes No No No
Standardization Euroflow EuroMRD Not reported No
NA — not available data
Table 2. List of the most useful antigens allowing normal and abnormal plasma cells (PC) discrimination (sources [14, 15])
Tabela 2. Lista najbardziej użytecznych antygenów do różnicowania prawidłowych i nieprawidłowych komórek plazmatycz-
nych (PC) (źródła [14, 15])
Antigen Normal expression Abnormal expression Patient’s expression [%] Diagnostics/
/monitoring
CD19 Positive (> 70%) Negative 95 Essential
CD56 Negative (< 15%) Strongly positive 75 Essential
CD20 Negative (0%) Positive 30 Recommended
CD28 Negative* (< 15%) Strongly positive 15–45 Recommended
CD27 Strongly positive (100%) Weak/negative 30–45 Recommended
CD81 Positive (100%) Weak/negative 20–50* Recommended
CD117 Negative (0%) Positive 30 Recommended
CD200 Negative (0%) Positive 75* Useful
*Own results
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immunofluorescence was required [21]. Presence/ 
/absence of clonal cells was based upon the k/l ratio 
which required a minimum of 100 PC for analysis, 
an abnormal ratio reflecting presence of an abnor-
mal clone was k/l of > 4:1 or < 1:2 [21]. Then the 
term MFC remission was used and patients were 
considered to be in MFC remission when MM-PC 
were undetectable in the BM sample at the MFC 
sensitivity limit of 10–4 (ie, 1 MM-PC in 104 N-PC). 
Only 4-colour MFC was used and a minimum of 3 × 
× 105 BM cells was acquired [10]. Later, the upda-
ted International Myeloma Working Group (IMWG) 
response criteria in 2011 incorporated some new 
designations to traditional CR definitions and im-
munophenotypic CR (iCR, sCR+) was defined as 
mentioned in previous sentence [10, 22]. Recently 
published IMWG MRD criteria defines flow MRD- 
-negative (MRD–) sample as an absence of phe-
notypically aberrant clonal plasma cells by NGF 
on BM aspirates using the EuroFlow standard 
operation procedure for MRD detection in MM 
(or validated equivalent method) with a minimum 
sensitivity of 1 in 105 nucleated cells or higher [18].
Highly sensitive MFC and standardisation
MFC seems to be the most perspective appro-
ach for detection of MRD in MM in terms of speed, 
price and availability of method. Applicability of MFC 
is over 90% of MM patient regardless of the kno-
wledge of the phenotype in time of diagnosis. The 
initial lower sensitivity of the method (when used 
4-colour flow cytometry) was increased by simul-
taneous detection of 8 markers/fluorochromes and 
acquisition of sufficient number of leukocytes in 1 
run up to 10–7, thus MFC is comparable with techni-
ques based on molecular level [7]. The technique has 
been modified to include an initial bulk lysis step to 
consistently measure more than 5 × 106 leucocytes 
per tube. Transition to the quantitative assessment 
of residual clonal PC will improve predictive poten-
tial of analyses as higher logarithms of clonal PC 
depletion significantly improved the length of OS 
[12]. But harmonisation and/or standardisation of 
MFC in MM are still relatively open as majority of 
clinical labs use their own protocols which are not 
inter-laboratory comparable (Figure 1) and often 
not sufficient enough in a sensitivity manner [4].
Project EuroFlow offers standardized process 
of sample preparation and data acquisition when 
defined validated panels of selected and verified 
markers are used for every type of haematological 
malignancy. Also innovative software Infinicyt for 
data analysis is used [23]. Original EuroFlow pa-
nel designed for PCD was not sufficient for MRD 
detection so 2nd generation of panel was developed 
(Table 3). This can identify clonal PC on a back-
ground of normal regenerating BM (Figure 1) [8]. 
The novel NGF-MRD approach takes advantage 
of innovative tools and procedures recently de-
veloped by the EuroFlow Consortium for sample 
preparation, antibody panel construction (including 
choice of type of antibody and fluorochrome), and 
automatic identification of PC against reference 
databases of normal and patient BM. An optimized 
2-tube 8-color antibody panel was constructed 
in five cycles of design-evaluation-redesign. In 
addition, a bulk-lysis procedure was established 
for acquisition of ≥ 107 cells/sample. Prospective 
validation of the whole procedure at two distinct 
centers confirmed its robustness and significantly 
greater sensitivity vs. conventional 8-color MRD 
approaches, comparable to current NGS methods, 
with an improved prediction of patient outcome 
[7]. On the other hand, semi-standardised approach 
is available from Beckman Coulter Company as 
premixed dry tubes combining 8 surface markers 
(CD38/CD45/CD81/CD27/CD19/CD200/CD138/ 
/CD56) for effective detection of clonal PC without 
clonality assessment (Figure 2).
Preanalytical rules
It is very important to obtain BM sample not 
diluted by peripheral blood, where marrow elements 
must be present, for obtaining a high quality results. 
There is a preference of EDTA anticoagulants as 
Heparin decrease CD138 intensity and PC should 
be less recognisable in context of whole leukocytes. 
When transportation of sample is needed, only the 
room temperature must be used. Analysis must be 
done until 36 hours from sample acquisition [4, 24].
Trouble shooting
Because of reduced number of PC after tre-
atment, the procedure for cell concentration must 
be used (bulk lysis), to allow MRD assessment 
without loss of cell subpopulation, and to acquire 
at least limit of detection (LOD) and better limit 
of quantification (LOQ) of method [25]. Using of 
targeted therapies as anti-CD38 (daratumumab) 
may complicate analysis by home-made protocols, 
but replacement of CD38 by CD229 and/or using 
multiepitope CD38 resolve that problem [26]. The 
therapy-induced clonal selection could be already 
present at the MRD stage, where chemoresistant 
PC show a singular phenotypic signature that may 
result from the persistence of clones with different 
genetic and gene expression profiles [27]. Although 
characteristic phenotype profile of clonal PC is 
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already known (Table 2), their detection should be 
impossible in small part of patients with atypical 
and/or changed profile (diagnostic vs. MRD antige-
nic profile), where different spectrum of antibodies 
should be used. Analysis of listmodes without SW 
assistance requires well educated operator and it 
is relatively time consuming.
Results report
The reporting of results to the clinicians 
should be descriptive and clear including % of 
plasma cells from leukocytes, % of clonal PC from 
whole PC population, phenotype of clonal cells, 
and sensitivity of analysis. Unsuitable and/or not 
representative samples should be reported.
Clinical relevancy  
of MFC-MRD assessment
Previous approaches to measurement of MRD 
levels were based on morphological assessment of 
BM, analysis of the paraprotein levels, or polymera-
se chain reaction (PCR) analysis of the immunoglo-
bulin heavy chain variable-diversity-joining (VDJ) 
region. Historically, first results demonstrated the 
clinical importance of MFC in MRD detection, 
whichwere published in 2002, when Rawstron at 
al. shown that analysis of normal and neoplastic PC 
levels is more sensitive than IFx [19]. Patients with 
detected neoplastic PC had a significantly shorter 
PFS than those with no detectable disease (median 
20 months vs. > 35 months, p = 0.003). Neoplastic 
PC were detectable in 27% (9 of 33) of IFx(–) CR 
patients. These patients had a significantly shorter 
PFS than IFx(–) patients with no detectable neopla-
stic PC (p = 0.04) [19]. Similarly San Miguel et al. 
[20] found out that treatment-induced changes in 
the PC compartment correlated with disease outco-
me and patients in whom at least 30% of gated PC 
had a normal phenotype after treatment with a sig-
nificantly longer PFS (60 ± 6 vs. 34 ± 12 months, 
p = 0.02). Detailed analysis of newly diagnosed MM 
Figure 1A–H. Different approaches of multiparametric flow cytometry of minimal residual disease (MFC-MRD) analy-
sis. Comparison of “home-made” (A–D) and 2nd generation of Euroflow PCD (E–H) protocol was done. Almost similar 
position of polyclonal (n-PCs, blue dots) and clonal (a-PCs, red dots) plasma cells (PCs) are visualised. Data acquired 
on BD FACSCanto II with Diva SW (BD Biosciences) and reanalysed by Infinicyt SW (Cytognos)
Rycina 1A–H. Odmienne podejścia do analizy minimalnej choroby resztkowej (MRD) metodą wieloparametrycznej cy-
tometrii przepływowej (MFC). Przeprowadzono porównanie analizy za pomocą własnego protokołu typu home-made 
(A–D) i protokołu Euroflow PCD drugiej generacji (E–H). Zwraca uwagę podobne położenie poliklonalnych (n-PCs, 
niebieskie punkty) i klonalnych (a-PC, czerwone punkty) plazmocytów (PC). Akwizycję danych przeprowadzono na 
cytometrze przepływowym BD FACSCanto II z oprogramowaniem Diva SW (BD Bioscience); ponownej analizy danych 
dokonano przy użyciu oprogramowania Infinicyt SW (Cytognos)
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patients treated in Spanish the GEM2000 protocol 
showed that PFS (median 71 vs. 37 months, p < 
< 0.001) and OS (median not reached vs. 89 months, 
p = 0.002) were longer in patients who were MRD(–) 
versus MRD(+) at day 100 after autologous stem 
cell transplantation (ASCT). Similar prognostic 
differentiation was seen in patients who achieved 
IFx(–) complete response after ASCT. Moreover, 
MRD(–)IFx(–) patients and MRD(–)IFx(+) pa-
tients had significantly longer PFS than MRD(+)
IFx(–) patients. Multivariate analysis identified 
MRD status by MFC at day 100 after ASCT as the 
most important independent prognostic factor for 
PFS (hazard ratio [HR] = 3.64, p = 0.002) and OS 
(HR = 2.02, p = 0.02) [10]. Results from Medical 
Research Council (MRC) Myeloma IX trial has 
Table 3. Development of Euroflow PCD panel (sources [7, 23])
Tabela 3. Opracowanie panelu Euroflow PCD (źródła [7, 23])
1st PCD generation PB PO FITC PE PerCP-Cy5.5 PC7 APC APC-H7
PCD1 CD45 CD138 CD38 CD28 CD27 CD19 CD117 CD81
PCD2 CD45 CD138 CD38  CD56 b2m CD19 cy Igk cy Igl
2nd PCD generation BV421 BV510 FITC PE PerCP-Cy5.5 PC7 APC APC-C750
PCD1 CD138 CD27 CD38 CD56 CD45 CD19 CD117 CD81
PCD2 CD138 CD27 CD38 CD56 CD45 CD19 cy Igk cy Igl
PB — pacific blue; PO — pacific orange; FITC — fluoresceinisothiocyanate; PE — phycoerythrin; PerCP-Cy5.5 — perridin chlorophyll-cyanine 5.5; PC7 — phycoerythrin-
-cyanine 7; APC — allophycocyanin; APC-H7 — allophycocyanin-H7; BV421 — brilliant violet 421; BV510 — Brilliant Violet 510; APC-C750 — allophycocyanin-C750
Figure 2A–H. Polychromatic analysis of plasma cells (PCs) in daratumumab treated multiple myeloma. Comparison 
of “home-made” (A–D) and Duraclone RE PC (E–H) protocol was done. Phenotype of clonal PCs (red dots) is similar 
CD19–CD56+CD27– (B, C, F, G) with high CD138 expression (A, E) in both approaches. Clonality assessment con-
firmed cytoplasmic expression of lambda light Ig chain (D), low CD81 and higher CD200 expression is relevant to 
pathological PCs as well (H). Data acquired on BD FACSCanto II with Diva SW (BD Biosciences) and reanalysed by 
Infinicyt SW (Cytognos)
Rycina 2A–H. Wielokolorowa analiza komórek plazmatycznych (PC) chorego na szpiczaka plazmocytowego leczonego 
daratumumabem. Przeprowadzono porównanie analizy za pomocą własnego protokołu typu home-made (A–D) i pro-
tokołu Duraclone RE PC (E–H). W obu podejściach fenotyp PC jest podobny: CD19–CD56+CD27– (B, C, F, G) z wysoką 
ekspresją CD138 (A, E). Ocena klonalności potwierdziła cytoplazmatyczną ekspresję lekkiego łańcucha Ig lambda (D); 
niska ekspresja CD81 i wyższa Cd200 jest również typowa dla patologicznych plazmocytów (H). Akwizycję danych 
przeprowadzono na cytometrze przepływowym BD FACSCanto II z oprogramowaniem Diva SW (BD Bioscience); 
ponownej analizy danych dokonano przy użyciu oprogramowania Infinicyt SW (Cytognos)
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shown that absence of MRD at day 100 after ASCT 
was highly predictive of a favorable outcome (PFS, 
p < 0.001; OS, p = 0.0183). This outcome advan-
tage was demonstrable in patients with favorable 
and adverse cytogenetics (PFS, p = 0.014 and 
p < 0.001, respectively) and in patients achieving 
IFx(–) CR (PFS, p < 0.0068). The effect of mainte-
nance thalidomide was assessed, with the shortest 
PFS demonstrable in those MRD(+) patients who 
did not receive maintenance and longest in those 
who were MRD(–) and did receive thalidomide 
(p < 0.001). Further analysis demonstrated that 
28% of MRD(+) patients who received maintenan-
ce thalidomide became MRD(–). MRD assessment 
after induction therapy in the non-intensive-
-pathway patients did not seem to be predictive of 
outcome (PFS, p = 0.1) [28]. Also was demonstra-
ted that the prognostic impact of MRD following 
ASCT is independent of the induction therapy 
received [29]. Surprisingly, MFC-MRD monitoring 
has the prognostic value also in relapsed MM and is 
one of the most relevant prognostic factors in elder-
ly MM patients, irrespectively of age or cytogenetic 
risk [11, 30]. Using NGF in multicentre evaluation 
of 110 follow-up BM from MM patients in very good 
partial response (VGPR) or CR showed a higher 
sensitivity for NGF-MRD vs. conventional 8-color 
MFC-MRD with MRD(+) rate of 47 vs. 34% (p = 
= 0.003). Thus, 25% of patients classified as MRD(–) 
by conventional 8-color MFC were MRD(+) by 
NGF, translating into a significantly longer PFS 
for MRD(–) vs. MRD(+) CR patients by NGF 
(75% PFS not reached vs. 7 months, p = 0.02) [7]. 
Very recent publication showed that achievement 
of CR in the absence of MRD negativity was not 
associated with prolonged PFS and OS compared 
with near-CR or partial response (median PFS 27, 
27, and 29 months, respectively; median OS, 59, 64, 
and 65 months, respectively). MRD(–) status was 
strongly associated with prolonged PFS (median 
63 months, p < 0.001) and OS (median not reached, 
p < 0.001) overall and in subgroups defined by prior 
transplantation, disease stage, and cytogenetics, 
with prognostic superiority of MRD negativity 
versus CR particularly evident in patients with 
high-risk cytogenetics [13].
Conclusion
As treatment strategies for MM become more 
effective and PFS becomes longer, assessing 
the treatment efficacy according to MRD levels 
becomes increasingly important. Different ap-
proaches for MFC-MRD monitoring are available. 
Implementation of highly sensitive automated 
MFC-MRD assessment by NGF should confirm 
a new biomarker for treatment effectivity assess-
ment and replace obsolete indicators defining 
clinical response and prediction of OS in MM. The 
prerequisite for that is standardisation of sample 
processing, sample and data analysis and verifica-
tion of this approach in clinical studies.
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